Genmab — Juni 2017
-
Helge, der er meget Trump ikke har kunnet levere i sin præsident periode, så lad os håbe det er en af dem

-
Roche får britisk oprejsning efter flere års kamp
Schweiziske Roche har efter fire års kamp endelig fået hul igennem med kræftmidlet Kadycla hos det britiske prioriteringsinstitut NICE.
(medwatch.dk)
-
NICE ligner mere og mere medicinverdenens svar på jyske kvinder - de er ligeglade med, hvad tingene koster. Bare de får en rabat...
-
Every month going by gives more proof of the benefits of dara. Even if NICE thinks the cost/benefit is too high at this moment, at some point they will have to approve if Dara PFS is getting longer and longer. It is just a matter of time in my opinion. I dont think Janssen should start discounting too heavily
just yet. -
Sorry Sukker..Sidder i møde. Smed linket for at fortælle at Trump var på banen igen over for medicinpriserne. Ved godt at han ikke har magt som han har agt.
-
https://clinicaltrials.gov/ct2/show/NCT01946477
Er det ud fra denne her de har søgt? -
Kite får PR for sin CD19 CAR-T i R/R NHL http://www.targetedonc.com/news/ktec19-granted-priority-review-by-fda-for-nonhodgkin-lymphoma
-
-
Den her pdufa gør vist markedet lidt nervøst - volumen er helt væk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind